These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 19234707)

  • 1. Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.
    Di Stasi SM; Riedl C
    World J Urol; 2009 Jun; 27(3):325-30. PubMed ID: 19234707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Intravesical therapy with mitomycin through electromotive drug administration].
    Verri C; Liberati E; Celestino F; De Carlo F; Torelli F; Di Stasi SM
    Urologia; 2013; 80(2):105-11. PubMed ID: 23852927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical electromotive drug administration for non-muscle invasive bladder cancer.
    Jung JH; Gudeloglu A; Kiziloz H; Kuntz GM; Miller A; Konety BR; Dahm P
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011864. PubMed ID: 28898400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
    Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes.
    Racioppi M; Di Gianfrancesco L; Ragonese M; Palermo G; Sacco E; Bassi PF
    BMC Cancer; 2018 Dec; 18(1):1224. PubMed ID: 30522445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer.
    Melgarejo-Segura MT; Morales-Martínez A; Yáñez-Castillo Y; Arrabal-Polo MÁ; Gómez-Lechuga P; Pareja-Vílchez M; Jiménez-Moleón JJ; Martín MA
    Urol Oncol; 2023 Apr; 41(4):166-176. PubMed ID: 36328923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
    Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM
    Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure.
    Juvet T; Mari A; Lajkosz K; Wallis CJ; Kuk C; Erlich A; Krimus L; Fleshner NE; Kulkarni GS; Zlotta AR
    Urol Oncol; 2020 Nov; 38(11):850.e9-850.e15. PubMed ID: 32712139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.
    Di Stasi SM; Liberati E; Dutto L; Verri C
    Arch Ital Urol Androl; 2008 Dec; 80(4):157-61. PubMed ID: 19235432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravesical Treatment with Electro-Mediated Administration of Mytomicin C as Prophylaxis for Intermediate and High-Risk Nonmuscle-Invasive Bladder Cancer: A Retrospective Multicenter Study.
    Carando R; Zazzara M; Cotrufo S; Ludovico GM
    Urol Int; 2019; 103(3):285-290. PubMed ID: 31461726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical electro-osmotic administration of mitomycin C.
    Di Stasi SM; Verri C; Celestino F; De Carlo F; Pagliarulo V
    Urologia; 2016 Oct; 83(Suppl 2):18-23. PubMed ID: 27716887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Non-muscle invasive bladder cancer: safety of postoperative EMDA-assisted instillation of mitomycin].
    Rehme C; Niedworok C; Rübben H; Vom Dorp F
    Urologe A; 2015 Feb; 54(2):235-8. PubMed ID: 25316185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single ablative intravesical electromotive mitomycin C administration for small non-muscle-invasive bladder cancer: a prospective study.
    Decaestecker K; Lumen N; Van Camp C; Oosterlinck W
    Acta Clin Belg; 2018 Oct; 73(5):324-327. PubMed ID: 29451102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential Treatment With Bacillus Calmette-Güerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG Failure.
    Sanz Gómez I; Huguet J; Bravo A; Robalino J; Rodríguez Faba Ó; Territo Á; Gaya JM; Palou J; Breda A
    Clin Genitourin Cancer; 2023 Aug; 21(4):e286-e290. PubMed ID: 37076337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytological and histological changes in the urothelium produced by electromotive drug administration (EMDA) and by the combination of intravescical hyperthermia and chemotherapy (thermochemotherapy).
    Pierconti F; Straccia P; Emilio S; Bassi PF; De Pascalis I; Marques RC; Volavsek M; Larocca LM; Lopez-Beltran A
    Pathol Res Pract; 2017 Sep; 213(9):1078-1081. PubMed ID: 28843746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [EMDA with MMC. Critical review.].
    Solsona E
    Arch Esp Urol; 2018 May; 71(4):409-416. PubMed ID: 29745930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
    Melgarejo Segura MT; Morales Martínez A; Yáñez Castillo Y; Arrabal Polo MÁ; Gómez Lechuga P; Pareja Vílchez M; Arrabal Martín M
    Urol Oncol; 2023 Feb; 41(2):109.e1-109.e8. PubMed ID: 36379812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle?
    Busetto GM; Finati M; Chirico M; Cinelli F; D'Altilia N; Falagario UG; Sanguedolce F; Del Giudice F; De Berardinis E; Ferro M; Crocetto F; Porreca A; Di Gianfrancesco L; Calo' B; Mancini V; Bettocchi C; Carrieri G; Cormio L
    World J Urol; 2023 May; 41(5):1329-1335. PubMed ID: 36971825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study.
    Brausi M; Campo B; Pizzocaro G; Rigatti P; Parma A; Mazza G; Vicini A; Stephen RL
    Urology; 1998 Mar; 51(3):506-9. PubMed ID: 9510365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study.
    Arrabal Polo MÁ; Melgarejo Segura MT; Yáñez Castillo Y; Morales Martínez A; Pareja Vílchez M; Arrabal Martín M
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7453-7459. PubMed ID: 36952006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.